GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043516 describes the biological process that modulates the frequency, rate, or extent of the p53-class mediator signal transduction cascade triggered by DNA damage.
• The core of this process is the stabilization and activation of the p53 tumor suppressor, which orchestrates cell-cycle arrest, DNA repair, senescence, or apoptosis.
• Key regulators include kinases such as ATM, ATR, CHK1, CHK2, and the ubiquitin-proteasome system that controls p53 turnover.
• Dysregulation of this process is linked to cancer, chemoresistance, and impaired DNA repair, making it a major therapeutic target.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect the causal roles of genes in this pathway.
• EDITGENE provides end-to-end services for building and screening such models, including CRISPR library screening and bioinformatics analysis.
Description
The Gene Ontology term GO:0043516, regulation of DNA damage response, signal transduction by p53 class mediator, defines any process that modulates the frequency, rate, or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage. This term captures the regulatory layer that sits upstream and within the p53 signaling axis, ensuring that the DNA damage response is appropriately scaled to the type and severity of the lesion. Because p53 is a central hub for genome maintenance, understanding how its damage-induced signal transduction is regulated is fundamental to cancer biology, aging research, and the development of targeted therapies. The p53 pathway is activated by diverse genotoxic stresses, including double-strand breaks, replication stress, and oxidative damage. Once activated, p53 transactivates target genes that mediate cell-cycle checkpoints, DNA repair, apoptosis, and senescence. The regulation of this signal transduction cascade involves post-translational modifications, protein-protein interactions, and feedback loops that fine-tune p53 activity. Disruption of these regulatory mechanisms can lead to unchecked proliferation, genomic instability, and tumorigenesis. Researchers studying GO:0043516 aim to identify the molecular players that control p53 signaling, determine how their dysfunction contributes to disease, and evaluate their potential as drug targets. This article integrates authoritative QuickGO annotations with verified PubMed literature to provide a research-grade overview of the term, its core mechanisms, key genes, disease relevance, and experimental strategies for investigation.
regulation of DNA damage response, signal transduction by p53 class mediator At A Glance
| GO ID | GO:0043516 |
|---|---|
| GO term | regulation of DNA damage response, signal transduction by p53 class mediator |
| Ontology | biological_process |
| Synonym | regulation of p53 induced by DNA damage response |
| Major function | Modulates the p53-mediated DNA damage signaling cascade |
| Key upstream activators | ATM, ATR, DNA-PK, CHK1, CHK2 |
| Key downstream effectors | CDKN1A (p21), MDM2, BAX, PUMA, GADD45 |
| Cellular outcomes | Cell-cycle arrest, DNA repair, apoptosis, senescence |
| Disease relevance | Cancer, chemoresistance, genomic instability |
What Is GO:0043516?
GO:0043516 is a biological process term that encompasses any regulatory event that changes the frequency, rate, or extent of the p53-class mediator signal transduction cascade initiated by DNA damage. In simpler terms, it is the set of controls that decide how strongly, how long, and in what context the p53 damage response operates.
Why Is regulation of DNA damage response, signal transduction by p53 class mediator Important in Cell Biology?
GO:0043516 is critically important because it governs the cellular decision between survival and death after DNA damage. Proper regulation of p53 signaling ensures that damaged cells either repair their DNA or are eliminated, thereby preventing the propagation of mutations. When this regulation fails, cells can bypass checkpoints, accumulate genomic alterations, and become malignant. Moreover, the efficacy of many anticancer therapies, such as doxorubicin and cisplatin, depends on an intact p53 damage response, and its dysregulation contributes to chemoresistance. Thus, understanding this process is essential for cancer biology, drug development, and precision medicine.
• Maintains genomic stability by coordinating DNA repair and cell-cycle checkpoints.
• Determines cell fate after DNA damage: survival, senescence, or apoptosis.
• Mutations in p53 or its regulators are among the most common events in human cancers.
• Modulates sensitivity to chemotherapy and radiotherapy.
• Involved in aging and degenerative diseases through accumulation of DNA damage.
• Provides targets for cancer therapy, including MDM2 inhibitors and checkpoint kinase inhibitors.
• Essential for understanding tissue-specific responses, such as in ovarian protection by AMH.
• Serves as a paradigm for signal transduction regulation in systems biology.
• Enables development of biomarkers for DNA damage and p53 pathway activity.
• Facilitates CRISPR-based functional genomics to identify novel regulators.
What Happens During regulation of DNA damage response, signal transduction by p53 class mediator?
DNA Damage Sensing and ATM/ATR Activation
In simple terms: When DNA breaks, sensor proteins alert the cell and switch on the p53 pathway.
The process begins with the detection of DNA lesions, particularly double-strand breaks (DSBs), by the MRN complex and other sensors. This recruits and activates the kinases ATM and ATR, which phosphorylate downstream targets including CHK1 and CHK2. These kinases amplify the damage signal and phosphorylate p53 at multiple residues, disrupting its interaction with MDM2 and leading to p53 stabilization.
p53 Stabilization and Post-Translational Modifications
In simple terms: The p53 protein is protected from degradation and modified so it can act as a transcription factor.
Under normal conditions, p53 is kept at low levels by MDM2-mediated ubiquitination and proteasomal degradation. Upon DNA damage, phosphorylation of p53 by ATM/ATR and CHK kinases, as well as acetylation and methylation, prevent MDM2 binding and promote p53 accumulation. This stabilization is a key regulatory step in GO:0043516, as it determines the magnitude and duration of the p53 response.
Transcriptional Activation of p53 Target Genes
In simple terms: Active p53 turns on a set of genes that stop the cell cycle or trigger repair or death.
Stabilized p53 binds to specific DNA response elements and activates transcription of target genes such as CDKN1A (p21), which induces cell-cycle arrest, and GADD45, which supports DNA repair. Depending on the context, p53 also induces pro-apoptotic genes like BAX and PUMA, leading to programmed cell death. The balance between these outcomes is regulated by cofactors and post-translational modifications.
Feedback Regulation and Signal Attenuation
In simple terms: The cell has brakes to turn off the p53 response once damage is fixed.
To prevent excessive or prolonged p53 activity, negative feedback loops are engaged. MDM2, itself a p53 target, promotes p53 degradation, while phosphatases such as WIP1 dephosphorylate and inactivate ATM and p53. Additionally, ubiquitin ligases like FBXL20 can target components of the autophagy machinery, linking p53 to receptor degradation and metabolic checkpoints. This feedback ensures that the DNA damage response is transient and proportionate.
Crosstalk with Other Signaling Pathways
In simple terms: The p53 damage response talks to other cellular pathways to coordinate the overall stress response.
The p53 pathway intersects with autophagy, metabolism, and cell survival signaling. For example, p53 controls Vps34 ubiquitination via FBXL20, influencing autophagy and receptor degradation. In ovarian biology, anti-Müllerian hormone (AMH) modulates the DNA damage response and cell fate, protecting against doxorubicin-induced damage. These crosstalks highlight the integrative nature of GO:0043516.
Key Genes Involved in GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator
The following genes and proteins are central to the regulation of the p53-mediated DNA damage response, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Tumor suppressor; transcription factor that induces cell-cycle arrest, apoptosis, senescence | Most frequently mutated gene in cancer; core of GO:0043516 |
| MDM2 | E3 ubiquitin ligase; negative regulator of p53 stability | Target for cancer therapy; feedback regulator |
| ATM | Kinase that senses DSBs and phosphorylates p53, CHK2 | Master upstream activator; mutations cause ataxia-telangiectasia |
| ATR | Kinase that responds to replication stress and phosphorylates CHK1 | Essential for replication checkpoint; drug target |
| CHEK1 | Effector kinase downstream of ATR; phosphorylates p53 and CDC25 | Checkpoint regulator; inhibitor in clinical trials |
| CHEK2 | Effector kinase downstream of ATM; phosphorylates p53 | Germline mutations increase cancer risk |
| CDKN1A | p21; mediates p53-induced cell-cycle arrest | Biomarker of p53 activity; therapeutic target |
| BAX | Pro-apoptotic Bcl-2 family member; induced by p53 | Determines apoptotic response to DNA damage |
| BBC3 | PUMA; pro-apoptotic BH3-only protein induced by p53 | Key mediator of p53-dependent apoptosis |
| GADD45A | Growth arrest and DNA damage-inducible gene; supports repair | Involved in nucleotide excision repair and cell cycle |
| FBXL20 | E3 ubiquitin ligase; targets Vps34 for degradation under p53 control | Links p53 to autophagy and receptor degradation |
| HIC1 | Transcriptional repressor; regulates p53 and DNA damage response | SNPs may affect cancer susceptibility |
| SRSF4 | Splicing factor; modulates pre-mRNA splicing upon cisplatin damage | Affects apoptosis and chemosensitivity |
| CAMK1 | Calcium/calmodulin-dependent kinase; involved in phosphoinositide signaling | Potential role in HCC and DNA damage response |
| AMH | Anti-Müllerian hormone; protects ovarian cells from doxorubicin | Regulates cell fate and DNA damage response |
| VPS34 | Phosphatidylinositol 3-kinase; regulates autophagy | Ubiquitinated by FBXL20 in p53-dependent manner |
| MIR34A | microRNA regulated by p53; modulates apoptosis and metabolism | Lauric acid modulates its expression in cancer cells |
How Is regulation of DNA damage response, signal transduction by p53 class mediator Regulated?
The regulation of GO:0043516 is achieved through multiple layers. Upstream, ATM and ATR kinases are activated by DNA damage and phosphorylate p53 and its regulators. Post-translational modifications, including phosphorylation, acetylation, methylation, and ubiquitination, control p53 stability and activity. The E3 ubiquitin ligase MDM2 provides a negative feedback loop, while FBXL20-mediated ubiquitination of Vps34 links p53 to autophagy. Additionally, hormonal signals such as AMH can modulate the DNA damage response in specific tissues. These regulatory mechanisms ensure that p53 activity is tightly controlled in intensity and duration.
regulation of DNA damage response, signal transduction by p53 class mediator and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Li-Fraumeni syndrome, multiple cancers | TP53 knockout and point-mutation cell lines; xenograft models |
| ATM | Ataxia-telangiectasia, breast cancer susceptibility | ATM knockout iPSCs; patient-derived cells |
| CHEK2 | Hereditary breast and colon cancer | CHEK2 knockout HCT116; knock-in of risk variants |
| MDM2 | Amplified in sarcomas and other cancers | MDM2 overexpression models; CRISPR knock-in of SNP309 |
| FBXL20 | Autophagy-related disorders, cancer | FBXL20 knockout HeLa; overexpression in p53-null cells |
Cancer and Chemoresistance
Dysregulation of GO:0043516 is a hallmark of cancer. TP53 mutations, found in over 50% of human tumors, disable the DNA damage response, allowing cells to proliferate despite genomic instability. Even when TP53 is wild-type, alterations in upstream regulators such as ATM, CHEK2, or MDM2 can impair p53 signaling and confer resistance to chemotherapy. For example, cisplatin-induced apoptosis requires proper splicing of pre-mRNA by SRSF4, and its dysregulation can lead to chemoresistance. Targeting the p53 pathway, including MDM2 inhibitors and CHK1/CHK2 inhibitors, is an active area of drug development.
Ovarian Protection and Reproductive Biology
AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage. This suggests that the p53 damage response is modulated in a tissue-specific manner and that hormonal signals can influence chemotoxicity. Understanding these interactions may lead to strategies for preserving fertility during cancer treatment.
Metabolic and Autophagy-Related Disorders
The p53 pathway intersects with autophagy through FBXL20-mediated Vps34 ubiquitination. This link suggests that dysregulation of GO:0043516 could contribute to diseases characterized by impaired autophagy, such as neurodegenerative disorders and metabolic syndromes. Additionally, microRNAs such as miR-34a, which are regulated by p53, can be modulated by dietary factors like lauric acid, influencing cancer cell growth.
Genetic Susceptibility and SNPs
Single nucleotide polymorphisms (SNPs) in genes encoding regulators of the p53 pathway, such as HIC1, can affect DNA damage response and cancer susceptibility. Computational analyses of these SNPs provide insights into their potential functional impact and may guide personalized medicine approaches.
From regulation of DNA damage response, signal transduction by p53 class mediator-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene alter p53 stabilization after DNA damage? | CRISPR knockout in U2OS or HCT116 cells, followed by Western blot for p53 |
| Does a specific point mutation in TP53 affect transcriptional activity? | CRISPR point-mutation knock-in of TP53 mutants in p53-null H1299 cells |
| Does a SNP in a regulator affect p53 binding? | Knock-in of the SNP using CRISPR in isogenic cell lines, followed by ChIP-seq |
| Does overexpression of a regulator protect against doxorubicin? | Doxycycline-inducible overexpression in ovarian cell lines, viability assays |
| What is the role of a splicing factor in cisplatin response? | CRISPR knockout of SRSF4 in HeLa, followed by apoptosis assays |
| Can a drug modulate p53-dependent autophagy? | CRISPR knockout of FBXL20 and VPS34, autophagy flux assays |
How to Study the regulation of DNA damage response, signal transduction by p53 class mediator Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes after DNA damage | Identify p53 target genes and regulatory networks |
| ChIP-seq | p53 binding sites across the genome | Map direct p53 targets and enhancer usage |
| Phospho-proteomics | Changes in phosphorylation of p53 and regulators | Determine kinase activity and signaling dynamics |
| CRISPR knockout screen | Loss-of-function effects on p53 pathway activity | Discover novel regulators of chemosensitivity |
| CRISPR activation screen | Gain-of-function effects on p53 signaling | Identify suppressors or enhancers of p53 response |
| Flow cytometry | Cell-cycle distribution and apoptosis | Quantify p53-dependent outcomes |
| Immunofluorescence | Subcellular localization of p53 and repair proteins | Assess nuclear accumulation and foci formation |
| Computational SNP analysis | Predicted impact of genetic variants on protein function | Prioritize SNPs in p53 regulators for experimental validation |
Genomic and Transcriptomic Profiling
RNA-seq and ChIP-seq are used to identify p53 target genes and measure transcriptional changes after DNA damage. These methods reveal the downstream effects of GO:0043516 and can uncover feedback regulators. Single-cell RNA-seq can dissect heterogeneity in p53 responses.
Proteomic and Post-Translational Modification Analysis
Mass spectrometry-based proteomics can quantify p53 phosphorylation, acetylation, and ubiquitination status. This is critical for understanding how regulators modify p53 stability and activity. Proximity labeling can identify dynamic interactors of p53 under damage conditions.
Functional Genomics with CRISPR Screens
Genome-wide CRISPR knockout or activation screens coupled with DNA-damaging agents can identify novel regulators of p53 signaling. These screens are powerful for discovering genes that modulate chemosensitivity. Computational analysis of screen data, such as pathway enrichment, helps prioritize hits.
Imaging and Cell-Based Assays
Live-cell imaging of fluorescently tagged p53 or its targets (e.g., p21) allows real-time monitoring of the DNA damage response. Apoptosis and cell-cycle assays (flow cytometry, Caspase-3 activity) measure the functional outcome of p53 activation.
How CRISPR Can Be Used to Study GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator
Knockout
CRISPR knockout is used to delete candidate genes and assess their requirement for p53 stabilization and downstream responses. For example, knocking out FBXL20 can reveal its role in p53-controlled autophagy. Knockout of SRSF4 impairs cisplatin-induced apoptosis, demonstrating its role in the DNA damage response.
Point Mutation
Point mutations can be introduced to model cancer-associated variants or to dissect phosphorylation sites. For instance, knocking in a kinase-dead mutation in ATM or a phosphorylation-deficient p53 mutant can clarify specific signaling events. This approach is valuable for studying SNPs identified in regulators like HIC1.
Knock-in
Knock-in of tagged versions of p53 or its regulators (e.g., GFP or HA tags) enables real-time imaging and biochemical purification. Knock-in of reporter genes under p53-responsive promoters allows sensitive monitoring of pathway activity. This is also used to create isogenic lines with disease-relevant alleles.
Overexpression
Overexpression of wild-type or mutant regulators can test sufficiency in activating or inhibiting p53 signaling. For example, overexpressing AMH in ovarian cells protects against doxorubicin-induced damage. Inducible overexpression systems avoid confounding effects of chronic high expression.
How EDITGENE Supports regulation of DNA damage response, signal transduction by p53 class mediator Research
Researchers studying regulation of DNA damage response, signal transduction by p53 class mediator-related genes often need to determine whether a candidate gene is causally involved in p53 stabilization, downstream transcription, or cell fate decisions. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models and to perform functional screens that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for regulation of DNA damage response, signal transduction by p53 class mediator research.
Frequently Asked Questions About regulation of DNA damage response, signal transduction by p53 class mediator
What is GO:0043516?
GO:0043516 is a Gene Ontology biological process term that describes the regulation of the DNA damage response signal transduction cascade mediated by p53 or equivalent proteins.
What genes are involved in regulation of DNA damage response by p53?
Key genes include TP53, MDM2, ATM, ATR, CHEK1, CHEK2, CDKN1A, BAX, and FBXL20, among others.
How does p53 get activated after DNA damage?
DNA damage activates ATM and ATR kinases, which phosphorylate p53 and its negative regulator MDM2, leading to p53 stabilization and activation.
What are the downstream effects of p53 activation?
p53 induces cell-cycle arrest, DNA repair, apoptosis, or senescence by transactivating target genes such as CDKN1A, GADD45, BAX, and PUMA.
Why is regulation of p53 signaling important in cancer?
Mutations in TP53 or its regulators are common in cancer and lead to genomic instability and chemoresistance, making this pathway a major therapeutic target.
How can CRISPR be used to study p53 signaling?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the causal role of specific genes in p53 activation and downstream responses.
What is the role of FBXL20 in p53 signaling?
FBXL20 is an E3 ubiquitin ligase that mediates Vps34 ubiquitination under p53 control, linking p53 to autophagy and receptor degradation.
Does AMH affect the DNA damage response?
Yes, AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage, indicating crosstalk with p53 signaling.
What methods are used to study GO:0043516?
Common methods include RNA-seq, ChIP-seq, phospho-proteomics, CRISPR screens, flow cytometry, and immunofluorescence.
How does cisplatin affect p53-mediated apoptosis?
Cisplatin induces DNA damage and modulates pre-mRNA splicing via SRSF4, which influences apoptosis and chemosensitivity.
Conclusion
GO:0043516 encompasses the critical regulatory mechanisms that control p53-mediated DNA damage signaling, a pathway essential for genome stability and cancer suppression. Understanding its components and regulation provides insights into tumorigenesis, chemoresistance, and potential therapeutic targets. Advances in CRISPR-based models and functional genomics are accelerating the discovery of novel regulators and their roles in health and disease. EDITGENE is committed to supporting this research with high-quality cell model engineering and screening services.
References
- 1. Nguyen NMP et al.. 2025. AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage.. Proc Natl Acad Sci U S A 122(5):e2414734122 PMID: 39874288
- 2. Panier S et al.. 2014. Double-strand break repair: 53BP1 comes into focus.. Nat Rev Mol Cell Biol 15(1):7-18 PMID: 24326623
- 3. Annanya A et al.. 2024. Computational Analysis of Single Nucleotide Polymorphisms in Human HIC1 Gene.. Cureus 16(3):e56664 PMID: 38646326
- 4. Achebouche R et al.. 2025. Assessment of chemical risk factor for breast cancer based on gene expression profiles.. Sci Rep 15(1):43983 PMID: 41408116
- 5. Xiao J et al.. 2015. FBXL20-mediated Vps34 ubiquitination as a p53 controlled checkpoint in regulating autophagy and receptor degradation.. Genes Dev 29(2):184-96 PMID: 25593308
- 6. Verma P et al.. 2020. Lauric Acid Modulates Cancer-Associated microRNA Expression and Inhibits the Growth of the Cancer Cell.. Anticancer Agents Med Chem 20(7):834-844 PMID: 32156243
- 7. Gabriel M et al.. 2015. Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis.. BMC Cancer 15:227 PMID: 25884497
- 8. Wang L et al.. 2014. CAMK1 phosphoinositide signal-mediated protein sorting and transport network in human hepatocellular carcinoma (HCC) by biocomputation.. Cell Biochem Biophys 70(2):1011-6 PMID: 24825433
